摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-吡咯甲酸甲酯 | 2703-17-5

中文名称
3-吡咯甲酸甲酯
中文别名
吡咯-3-羧酸甲酯;1H-吡咯-3-羧酸甲酯(9ci);1H-吡咯-3-甲酸甲酯;甲基1H-吡咯-3-羧酸乙酯
英文名称
methyl 1H-pyrrole-3-carboxylate
英文别名
methyl pyrrole-3-carboxylate;methyl 3-pyrrolecarboxylate;Pyrrol-3-carbonsaeure-methylester;Methylpyrrol-3-carboxylat;1H-pyrrole-3-carboxylic acid methyl ester
3-吡咯甲酸甲酯化学式
CAS
2703-17-5
化学式
C6H7NO2
mdl
MFCD00967074
分子量
125.127
InChiKey
WLBNVSIQCFHAQB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    85-89 °C
  • 沸点:
    284℃
  • 密度:
    1.184
  • 闪点:
    126℃

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    9
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.166
  • 拓扑面积:
    42.1
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 安全说明:
    S26,S37,S60
  • 危险类别码:
    R36/37/38
  • WGK Germany:
    3
  • 海关编码:
    2933990090
  • 储存条件:
    室温且干燥

SDS

SDS:94983ef26e06fba5243797de7a15ee01
查看

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : Methyl 1H-pyrrole-3-carboxylate
CAS-No. : 2703-17-5
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances



Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
The product does not need to be labelled in accordance with EC directives or respective national laws.
Other hazards - none

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C6H7NO2
Molecular Weight : 125,13 g/mol
Component Concentration
Methyl 1H-pyrrole-3-carboxylate
CAS-No. 2703-17-5 -

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
Indication of any immediate medical attention and special treatment needed
no data available

Section 5. FIRE-FIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Avoid
breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Store under inert gas.
Specific end uses
no data available

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at
the end of workday.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the
standard EN 374 derived from it.
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 85 - 89 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 0,868
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes
May cause eye irritation.
Additional Information
RTECS: Not available

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
no data available

Section 16. OTHER INFORMATION
Further information
Copyright 2011 Co. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used
only as a guide. The information in this document is based on the present state of our knowledge and is
applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Co., shall not be held liable for any damage
resulting from handling or from contact with the above product. See reverse side of invoice or packing slip
for additional terms and conditions of sale.

制备方法与用途

应用广泛,3-吡咯甲酸甲酯可用作有机合成中间体及医药中间体,主要应用于实验室研发和化工、制药行业的合成过程。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-吡咯甲酸甲酯 在 sodium hydroxide 作用下, 以 乙二醇 为溶剂, 反应 3.0h, 生成 吡咯
    参考文献:
    名称:
    吡咯的无金属定向C H硼化
    摘要:
    仍然明显缺乏开发能以选择性,实用,低成本和环境友好的模式快速构建复杂的有机硼酸酯的稳健策略。在这里,我们通过仅使用由新戊酰基引导的BBr 3避免了使用任何金属,为吡咯的位点选择性CH硼化开发了一种通用策略。通常,位点选择性主要受螯合和电子效应的影响,因此形成了多种C2硼化的吡咯,以抵抗空间效应。成型产品可以很容易地参与下游转型,从而实现了逐步经济的过程来获得立普妥(Lipitor)等药物。DFT计算(wB97X-D)证明了该反应的首选位置选择性。
    DOI:
    10.1002/anie.202016573
  • 作为产物:
    描述:
    1-(2-bromobenzenesulfonyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid methyl ester 在 palladium diacetate 、 potassium carbonate三苯基膦 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 18.0h, 以42%的产率得到3-吡咯甲酸甲酯
    参考文献:
    名称:
    一系列环磺酰胺的分子内Heck反应中的区域选择性:实验和计算研究。
    摘要:
    研究了一系列N-磺酰基-2,5-二氢-3-取代吡咯在分子内Heck反应中的区域选择性。这些衬底在新杂环形成的环尺寸方面没有偏见。结果表明,在一定条件下观察到了很高的区域选择性,并且在烯烃最受阻的末端存在潜在的碳-碳键形成趋势。对于两个示例(3 Me和3 t Bu),进行了DFT计算,结果表明,在这两种情况下,对于碳酸盐的建模过渡态,对于实验上优选的异构体,在能量上都较低。
    DOI:
    10.1002/chem.201201359
点击查看最新优质反应信息

文献信息

  • HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER
    申请人:Asana Biosciences, LLC
    公开号:US20160362407A1
    公开(公告)日:2016-12-15
    The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, Z, J, M, and R 1 to R 8 are defined herein, these compounds are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.
    本申请提供了新颖的杂环化合物及其药用可接受的盐。还提供了制备这些化合物的方法。这些化合物对抑制ERK1/2有用。通过向需要治疗的患者施用式(I)的一个或多个化合物的治疗有效量,其中X、Y、Z、J、M和R1至R8在此处定义,这些化合物在治疗与RAS/RAF/MEK/ERK通路失调相关的疾病方面是有效的。可以使用这些化合物治疗各种疾病,包括以异常细胞增殖为特征的疾病。在一个实施例中,该疾病是癌症。
  • A general N-alkylation platform via copper metallaphotoredox and silyl radical activation of alkyl halides
    作者:Nathan W. Dow、Albert Cabré、David W.C. MacMillan
    DOI:10.1016/j.chempr.2021.05.005
    日期:2021.7
    The catalytic union of amides, sulfonamides, anilines, imines, or N-heterocycles with a broad spectrum of electronically and sterically diverse alkyl bromides has been achieved via a visible-light-induced metallaphotoredox platform. The use of a halogen abstraction-radical capture (HARC) mechanism allows for room temperature coupling of C(sp3)-bromides using simple Cu(II) salts, effectively bypassing
    通过可见光诱导的属光氧化还原平台实现了酰胺、磺胺苯胺亚胺或N-杂环与广谱电子和空间多样化烷基的催化结合。卤素提取-自由基捕获 (HARC) 机制的使用允许使用简单的 Cu(II) 盐在室温下耦合 C( sp 3 )-化物,有效绕过通常与热诱导 S N 2 或 S相关的过高障碍N 1 N-烷基化。这种区域和化学选择性方案与 >10 类药物相关的N兼容- 亲核试剂,包括已建立的药剂,以及结构多样的伯、仲和叔烷基。此外,通过将N-亲核试剂与环丙基和未活化的烷基(与亲核取代途径不相容的底物)结合,突出了 HARC 方法与传统惰性偶联伙伴结合的能力。初步的机械实验验证了该平台的双重催化、开壳性质,这使得在传统的基于卤化物的N-烷基化系统中无法实现的反应性成为可能。
  • Antidiabetic pyrrolecarboxylic acids
    申请人:Pfizer Inc.
    公开号:US04282242A1
    公开(公告)日:1981-08-04
    Certain pyrrolecarboxylic and pyrroleacetic acid derivatives substituted on the pyrrole ring with thioether groups, acyl groups, phenyl, substituted phenyl, phenoxy, substituted phenoxy, benzyl or halo and optionally substituted on the pyrrole nitrogen with alkyl, and the pharmaceutically acceptable salts thereof, are useful in lowering the blood glucose levels of hyperglycemic animals.
    某些在吡咯环上用醚基团、酰基、苯基、取代苯基、苯氧基、取代苯氧基、苄基或卤素取代的吡咯羧酸吡咯乙酸生物,以及在吡咯氮上选择性地用烷基取代的药用可接受盐,对降低高血糖动物的血糖平是有用的。
  • The copper(<scp>ii</scp>)-catalyzed and oxidant-promoted regioselective C-2 difluoromethylation of indoles and pyrroles
    作者:Dong Zhang、Zheng Fang、Jinlin Cai、Chengkou Liu、Wei He、Jindian Duan、Ning Qin、Zhao Yang、Kai Guo
    DOI:10.1039/d0cc03345f
    日期:——
    highly selective C-2 difluoromethylation of indole derivatives was developed by using sodium difluoromethylsulfinate (HCF2SO2Na) as the source of difluoromethyl groups and a Cu(II) complex as the catalyst. Various substrates were well tolerated in this transformation and the desired products were obtained in moderate to good yields. Moreover, the late-stage C-2 difluoromethylation of bioactive molecules
    通过使用二甲基亚磺酸钠(HCF 2 SO 2 Na)作为二甲基的来源和Cu(II)络合物作为催化剂,开发了一种新颖且高效的吲哚生物高选择性C-2二甲基化方法。在这种转化中,各种底物都具有良好的耐受性,并且以中等至良好的产率获得了所需的产物。此外,以高收率实现了含有吲哚环的生物活性分子的后期C-2二甲基化。通常,该反应具有出色的官能团相容性,广泛的底物范围和出色的C-2选择性。
  • TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF
    申请人:Merck Patent GmbH
    公开号:US20160376283A1
    公开(公告)日:2016-12-29
    The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKKε inhibitors.
    本发明涉及式I化合物及其药用可接受的组合物,用作TBK/IKKε抑制剂
查看更多